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Summary
RNA interference (RNAi) is a process whereby short-
interfering RNAs (siRNA) silence gene expression in
a sequence-specific manner. We have screened a chemi-
cal library of substituted dihydropteridinones and iden-
tified a nontoxic, cell permeable, and reversible inhibi-
tor of the RNAi pathway in human cells. Biochemical
and fluorescence resonance-energy transfer experi-
ments demonstrated that one of the compounds,
named ATPA-18, inhibited siRNA unwinding that oc-
curred within 6 hr of siRNA transfection. Extracts
prepared from ATPA-18-treated cells also exhibited a
decrease in target RNA cleavage by activated RNA-
induced silencing complex (RISC*). Interestingly, when
activated RISC*, which harbors unwound antisense
siRNA, was treated with ATPA-18 in vitro, target RNA
cleavage was not affected, indicating that this com-
pound inhibited siRNA unwinding or steps upstream
of unwinding in the RNAi pathway. Our results also
establish the timing of siRNA unwinding and show
that siRNA helicase activity is required for RNAi.
ATPA-18 analogs will therefore provide a new class of
small molecules for studying RNAi mechanisms in a
variety of model organisms and deciphering in vivo
genetic functions through reverse genetics.
Introduction
RNA interference (RNAi), the process by which mRNA
is targeted for degradation by 21–23 nucleotide short-
interfering RNA (siRNA), has become key to establish-
ing connections between gene structure and function
in human cells by reverse genetics (reviewed in [1, 2]).
Because of its broad applications in biology and medi-
cine, understanding the fundamental mechanism of
RNAi phenomenon is of great importance. The current
model for how RNAi occurs in vivo is shown in Figure
1A. In the first step of RNAi induction, the 5# ends of
the siRNA duplex are phosphorylated, resulting in the
formation of an RNA-induced silencing complex (RISC)-
siRNA complex [3, 4]. Additional ATP-dependent events
take place next involving siRNA unwinding from the 5#
end of the antisense strand and activation of RISC*Correspondence: tariq.rana@umassmed.edu
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nue, Lexington, Massachusetts 02421.(RISC*) [5]. After siRNA-programmed RISC* (siRISC*)
activation, the antisense strand of the unwound siRNA
guides the siRISC* complex to the target mRNA [6, 7].
The guide antisense-strand base pairs with the target
mRNA, forming an A-form helical geometry recognized
by RISC* [3, 8]. In the final step, RISC* cleaves the target
mRNA [9]. RISC* can then be recycled to cleave an-
other mRNA [10].
Recently, structural and biochemical studies defined
Ago2 as the catalytic engine of RISC* that mediates the
cleavage of the target RNA in human cells [11–13].
Other components of RISC required for RNAi have re-
mained elusive, including the putative RNA helicase in-
volved in unwinding siRNA. To identify new components
of the RNAi pathway, we developed a screen for small
molecules that block ATP-dependent steps of RNAi.
Two small molecules identified in this screen were fur-
ther characterized and were shown to specifically in-
hibit an early step in the RNAi pathway.
Results and Discussion
We took a small-molecule-based approach to dissect
the ATP-dependent steps of the RNAi pathway. We syn-
thesized a small chemical library of substituted dihy-
dropteridinones as ATP analogs that contain both rigid
and flexible scaffolds (C.U.D. and T.M.R., unpublished
data) and screened their activities in a dual-fluores-
cence assay for RNAi induction [3]. In this assay, plas-
mids harboring enhanced green- and red-fluorescent
proteins (EGFP and RFP, respectively) were cotrans-
fected into HeLa cells with EGFP siRNA that targets
EGFP mRNA for degradation. The ratio of EGFP/RFP
fluorescence in the presence of siRNA was calculated
and normalized to the EGFP/RFP ratio of mock treated
cells. RNAi activity was then compared to RNAi in cells
transfected with EGFP siRNA and treated with an ATP
analog from the dihydropteridinones library. The screen
was designed to identify small molecule probes that
would specifically inhibit ATP-dependent events oc-
curring during RNAi and, in doing so, inhibit RNAi. We
identified two nontoxic compounds that showed concen-
tration-dependent inhibition of RNAi in the dual-fluo-
rescence assay. The structure of these compounds,
designated ATPA-18 and ATPA-21, and their associated
inhibitory activities are shown in Figure 1B.
To investigate whether ATPA-18 and ATPA-21 can in-
hibit RNAi against endogeneously expressed mRNA,
we tested their effect on RNAi targeted to human CDK9
mRNA. CDK9 is the cyclin-dependent kinase com-
ponent of the P-TEFb, CDK9-cyclinT1 complex, which
is involved in regulating transcription elongation [14].
CDK9 double-stranded siRNA wholly complementary
to CDK9 mRNA knocked down CDK9 protein levels
substantially, unlike mock or mismatched CDK9 siRNA-
treated cells (Figure 1C, lanes 1, 2, 7, 8 and 9). How-
ever, in the presence of increasing amounts of either
ATPA-18 or ATPA-21 up to 100 M, CDK9 protein levels
were restored to normal, endogenous levels in a dose-
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644Figure 1. Small-Molecule Inhibitors of RNA Interference in Human Cells
(A) Model for RNAi in human cells highlighting the requirement of ATP.
(B) ATPA-18 and ATPA-21 as inhibitors of RNA interference in human cells. RNAi activity was quantified by the dual-fluorescence assay [3]
and presented as the inhibition efficiency of target gene (EGFP) expression when cells were treated with 25 nM duplex siRNAs (DS) and small
molecule inhibitors at 0.5–50 M. Structures of the ATPA-18 and ATPA-21 exhibiting inhibition effects on RNAi are shown here.
(C) Effect of ATPA-18 and ATPA-21 on RNAi targeted to an endogenously expressed gene product. 150 nM CDK9 siRNA [14] were transfected
into HeLa cells with or without inhibitor. At 42 hr posttransfection, proteins in 60 g of total cell lysate were resolved by 10% SDS-PAGE,
transferred onto polyvinylidene difluoride membrane (PVDF membrane, Bio-Rad), and probed with antibodies against CDK9 (Santa Cruz). As
a loading control, the same membrane was also probed with anti-hCycT1 antibody (Santa Cruz). Protein contents were visualized with BM
Chemiluminescence Blotting Kit (Roche Molecular Biochemicals). Immunoblots were exposed to X-ray film (Kodak MR-1) for various times
(between 30 s and 5 min).dependent manner (Figure 1C, lanes 3–6 and 10–13).
iThese results suggested that the ATPA compounds
generally interfered with RNAi regardless of whether a
imRNAs were expressed episomally or endogenously,
and the degree of potency depended on the concentra- l
(tion of the ATPA.
We next examined the mechanism of how ATPA-18 r
and ATPA-21 induced their effects in vivo. One striking
observation was that both ATPA compounds were un- v
Aable to inhibit RNAi if cells were treated 6 hr after trans-
fection (compare blue bars to red bars in Figure 2A). a
tThis finding established that the timing of the step(s) of
the RNAi pathway affected by ATPA-18 and ATPA-21 s
noccurred between 0–6 hr posttransfection. Because
both compounds were showing identical effects, we R
ochose to further characterize ATPA-18 in our studies.First, localization patterns of siRNA were determined
n the presence and absence of 100 M ATPA-18. In the
bsence of ATPA-18, siRNA localized to areas surround-
ng the nucleus, and no significant differences in this
ocalization were observed in the presence of ATPA-18
Figure 2B). This suggested that ATPA-18 did not dis-
upt the cytoplasmic localization of siRNA [15–17].
The 5# phosphorylation state and the single-stranded
ersus double-stranded nature of siRNA treated with the
TPA-18 were analyzed to determine how ATPA-18 was
ffecting the phosphorylation state and duplex struc-
ure of siRNA. In this particular assay, the siRNA anti-
ense strands were biotinylated on their 3# end (desig-
ated AS-3#-Biotin) because this end is not required for
NAi [3, 6, 18]. The mobility of siRNAs was established
n a 20% polyacrylamide-7 M urea gel. When isolated in
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645Figure 2. Cellular Target for Small-Molecule Inhibitors of RNA Inter-
ference in Human Cells
(A) ATPA-18 and ATPA-21 affected the step(s) of the RNAi pathway
occurring between 0–6 hr posttransfection. RNAi activity was quan-
tified by the dual-fluorescence assay and presented as the inhibi-
tion efficiency of target gene (EGFP) expression [3]. Cells were
treated with 25 nM duplex siRNAs, and increasing concentrations
of ATPA-18 and ATPA-21 were added at the beginning of transfec-
tion (0 hr, blue bar) or at 6 hr posttransfection (red bar).
(B) Localization patterns of siRNAs were not changed by ATPA-
18. SS/AS-Alexa 568 duplex siRNAs with Alexa 568 labeling at the
antisense strand 3# terminus were transfected into HeLa cells, and
the distribution pattern was determined in the presence and ab-
sence of 100 M ATPA-18 at 6 hr posttransfection.
(C) Biotin pull-out assay indicating that helicase activity and not
kinase activity was the cellular target for small-molecule inhibitors
of RNAi in human cells. siRNA antisense strands were biotinylated
on their 3# end (designated AS-3#-Biotin). HeLa cells were cotrans-
fected with biotinylated EGFP duplex siRNA (SS/AS3#-Biotin) and
pEGFP-C1. siRNAs were isolated by streptavidin-magnetic beads
and then were subjected to phosphatase and kinase reactions.
Lanes 1–3 (marker lanes) contain 5#-end-labeled RNA sense
strands (ss) (lane 1), 3#-biotinylated antisense strands (AS3#-Biotin)
(lane 2), and heat-denatured (10 min at 95°C) siRNA duplexes (SS/
AS3#-Biotin) (lane 3). Isolated biotinylated siRNA are shown with
(lanes 5 and 7) or without SAP treatment (lanes 6 and 8). RNA iso-
lated as above from HeLa cells without siRNA transfection is shown
in lane 4.a duplex form, the sense strand and the AS-3#-Biotin
strands appeared as two distinct bands in the same lane
(Figure 2C, lanes 1–3). Streptavidin magnetic beads were
used to pull out biotinylated siRNAs from cells 6 hr
posttransfection, washed to remove unbound RNA, and
then split into two aliquots to determine if the 5# end ofthe antisense strand was being phosphorylated. One
aliquot was dephosphorylated with shrimp alkaline
phosphatase (SAP) and the siRNA 5# ends were labeled
with 32P by T4 polynucleotide kinase (PNK) reactions.
The other aliquot was subjected to 5#-end radiolabeling
by PNK without prior dephosphorylation by SAP. Cells
that were not transfected with siRNA did not show any
bands (Figure 2C, lane 4), indicating that the siRNAs
recovered were specific to those transfected into cells
and pulled out with streptavidin magnetic beads. In the
absence of ATPA-18, efficient 5# end radiolabeling was
observed only when siRNA was pretreated with SAP.
This indicated that the 5# ends had been phosphor-
ylated in vivo (Figure 2C, lanes 5 and 6), thereby pre-
venting the addition of a phosphate group without prior
removal of the phosphate group added in vivo. In ad-
dition, predominantly only the biotinylated antisense
strands were pulled out from cells in the absence of
ATPA-18. These results indicated that recovered
siRNAs were mostly single stranded, signifying that the
duplex had been unwound prior to removal from cells.
In the presence of 50 M ATPA-18, which was added
at the time of transfection, efficient 5#-end radiolabeling
was observed only when siRNA was pretreated with
SAP (Figure 2C, lanes 7 and 8), indicating that the 5#
ends had been phosphorylated in vivo, as was seen in
the absence of ATPA-18. This strongly suggested that
ATPA-18 was not blocking the siRNA 5# phosphoryla-
tion step of the RNAi pathway. However, in contrast to
what was observed in the absence of ATPA-18, a signif-
icant amount of sense strand siRNA was pulled out with
the biotinylated antisense strand upon treatment with
ATPA-18 (Figure 2C, lanes 7 and 8 arrows). The pres-
ence of both strands signified that the siRNA duplex
had not been efficiently unwound at the time AS-3#-
Biotin was recovered from the cell. This result demon-
strated that the ATPA-18 analog was specifically affecting
the unwinding step of the RNAi pathway, suggesting
that the target of ATPA-18 inhibition was an ATP-depen-
dent RNA helicase.
To directly study the effects of ATPA-18 on siRNA un-
winding in vivo, we designed fluorescence resonance
energy transfer (FRET) experiments to distinguish wound
and unwound siRNA. FRET, in which a fluorescent do-
nor molecule transfers energy via a nonradiative dipole-
dipole interaction to an acceptor molecule [19], is a
powerful spectroscopic technique for visualizing the
phenomenon associated with the distance change be-
tween donors and acceptors. The efficiency of FRET







in which R is the distance between donor and acceptor,
and R0 is the Förster distance. Practically, EFRET can be
calculated by measuring the donor fluorescence inten-
sity in the absence of an acceptor (ID) and in the pres-





In this work, Alexa Fluor 568 (donor) was conjugated
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646to the antisense siRNA (AS-Alexa 568) and Alexa Fluor
u647 (acceptor) labeled the sense siRNA (SS-Alexa 647).
Both donor and acceptor were conjugated at the 3#- d
iend of each strand (Figure 3). FRET would only be
observed when the labeled siRNA was in a duplex a
Estructure, and would not be observed when siRNA was
unwound (Figure 3A), providing an unambiguous [
pmethod of analyzing RNA helicase activity.
We observed fluorescence with the donor filter and f
unot the FRET filter when only AS-Alexa 568 was trans-
fected into cells (Figure 3B, left). FRET was not ob- o
Aserved when AS-Alexa 568/SS-Alexa 647 siRNA was
transfected into HeLa cells in the absence of ATPA-18 w
t(Figure 3B, second panel from left), indicating that siRNA
unwinding had occurred. In the presence of ATPA-18,
nfluorescence was observed with both the donor and
FRET filters. This indicated that unwinding had not oc- n
scurred and that ATPA-18 specifically inhibited siRNA
unwinding in vivo, corroborating the above biotin pull- w
pout analysis that showed siRNA in ATPA-18-treated
cells did not unwind at a high efficiency. The inhibitory w
seffect of ATPA-18 on siRNA unwinding was reversible
because FRET was lost when ATPA-18 was removed 2
qfrom the cell media for 12 hr, signifying that the RNA
helicase had regained the capacity to unwind siRNA. s
uThis loss of FRET is not likely due to siRNA degradation
because we observed RNAi over a period of 54 hr after wFigure 3. Effect of ATPA-18 on siRNA Unwind-
ing In Vivo
siRNA were labeled with Alexa 647 and Alexa
568 at the 3# terminus of the siRNA sense
and antisense strand, respectively. Duplex
siRNA (SS-Alexa 647/AS-Alexa 568) were
transfected into HeLa cells with or without
ATPA-18 treatment. Transfection mixtures were
removed at 6 hr posttransfection, and cells
were continuously cultured in the presence
or absence of ATPA-18. Cells were imaged
at 8 hr posttransfection. Cells were imaged
with a Leica confocal imaging system (TCS-
SP2) attached to a Leica DMIRE inverted
fluorescence microscope and equipped with
an acousto-optic tunable filter (AOTF) and a
tunable acousto-optical beam splitter (AOBS).
A 63×, 1.32 NA oil-immersion objective was
employed. For donor (AS-Alexa 568) detec-
tion, the fluorescence emission signal was
recorded at 585 ± 30 nm when excited at the
Alexa 568 excitation wavelength (543 nm).
For FRET signal detection, the fluorescence
emission signal was recorded at 675 ± 25 nm
when excited at the Alexa 568 excitation
wavelength (543 nm).removal of ATPA-18 (data not shown).Another approach for detecting FRET in siRNA was
tilized in which donor emission lost by energy transfer
uring FRET was restored by deliberately photobleach-
ng the acceptor fluorophore, abolishing its capacity as
n energy acceptor, to quantitatively determine the
FRET in vivo between AS-Alexa 568 and SS-Alexa 647
20, 21]. Unwound siRNA gives a very small EFRET, and
hotobleaching of the Alexa 647 would not affect the
luorescence of Alexa 568. If ATPA-18 inhibits siRNA
nwinding and FRET between Alexa 568 and Alexa 647
ccurs, photobleaching would result in an increment of
lexa 568 fluorescence intensity (Figure S1A available
ith this article online), and a high EFRET would be ob-
ained.
In the absence of ATPA-18, acceptor emissions were
ot detected, and a change in donor fluorescence was
ot detected after acceptor photobleaching (data not
hown), indicating that FRET had not occurred and un-
inding had taken place. In the presence of ATPA-18,
rior to acceptor photobleaching, the donor showed
eak fluorescence, whereas the acceptor displayed
trong fluorescence signals (Figure S1B, panels 1 and
). After photobleaching, donor fluorescence became
uite strong, acceptor fluorescence was no longer ob-
erved, and photobleaching efficiency was 94.8% (Fig-
re S1B, panels 3 and 4). The energy transfer efficiency
as calculated to be 77.9%. These results indicatedthat FRET occurred between AS-Alexa 568 and SS-Alexa
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647647 and strongly suggested that unwinding had not oc-
curred in the presence of ATPA-18.
To determine if ATPA-18 effects were specific to
double-stranded siRNA, we measured RISC* activity in
the presence and absence of ATPA-18 in vitro. In these
experiments, duplex siRNA was transfected into cells,
cells were harvested 24 hr post transfection, and the
extracts prepared from these transfected cells were in-
cubated with 32P-labeled target RNA in an in vitro
cleavage reaction [22, 23]. The cell extracts contain
GFP siRNA or let-7 microRNA (miRNA), which is a 21–
22 nt endogenous RNA that associates with RISC to
inhibit translation. The effect of ATPA-18 on RISC* ac-
tivity was measured by comparing target cleavage effi-
ciency observed in untreated in vitro cleavage reactions
to the cleavage efficiency seen when ATPA-18 was
added to reactions at increasing concentrations. Note
that the effect of ATPA-18 on RISC* in these extracts
would be specific to single-stranded and not double-
stranded siRNA or miRNA because both RNAs were un-
wound in vivo prior to harvesting. Neither siRNA- nor
miRNA-programmed RISC* activity were affected by
the addition of ATPA-18 (Figure S2A), suggesting that
single-stranded siRNA or miRNA complexed with RISC*
was not sensitive to this inhibitor. To test the effect of
ATPA-18 on target RNA cleavage prior to unwinding,
we transfected cells with siRNA and treated cells with
or without ATPA-18. Cell extracts were prepared, and in
vitro cleavage reactions were performed as described
above. Extracts from cells that were not treated with
ATPA-18 showed w40% cleavage, whereas extracts
from cells treated with ATPA-18 showed w18% cleav-
age (Figure S2B), suggesting that ATPA-18 was affect-
ing an early step in the RNAi pathway that occurred at
the step of or prior to siRNA unwinding. let-7-pro-
grammed RISC* was not affected by ATPA-18 in these
experiments (Figure S2B). Presumably, endogenous
let-7 miRNA was already unwound and associated with
activated RISC* prior to ATPA-18 treatment and, thus,
was not affected by an inhibitor of early steps in the
RNAi pathway.
Our experiments identified nontoxic, cell-permeable,
fast-acting, and reversible small molecules that modu-
late the RNA-interference pathway in human cells. This
reversibility provides a new strategy for modulating re-
verse genetics by using small molecules and RNAi to
exploit the control of gene expression and evaluate the
effects of gene knockdown. ATPA-18 was further char-
acterized as a potent, targeted inhibitor of a discrete
step of the RNAi pathway in human cells, and our re-
sults raise the possibility that ATPA-18 may inhibit a
specific ATP-dependent RNA helicase in human cells
during RNAi. This analysis of ATPA-18 showed that a
small molecule could be used to specifically inhibit an
early step in the RNAi pathway, which may include
siRNA entry into the pathway, RISC loading, and/or
siRNA unwinding. Our results also demonstrated in vivo
that events occurring prior to or at the step of siRNA
unwinding are ATP dependent and essential for RNAi
induction. Our studies also established the timing of
siRNA unwinding to be within the first 6 hr of transfec-
tion. However, once unwinding occurs within 6 hr of
siRNA transfection, RNAi cannot be inhibited by ATPA-
18, indicating that the unwinding step was not revers-
ible once completed. With the importance of theseearly steps in the RNAi pathway and unwinding now
established in vivo, current studies are focused on iso-
lating the ATP-dependent target of ATPA-18 and char-
acterizing its role in the RNAi pathway. Comparing the
effects of these inhibitors on the RNAi pathway in other
model organisms will also be interesting to study in
the future.
Significance
During RNA interference (RNAi), a double-stranded
small-interfering RNA (siRNA) in association with the
RNA-induced silencing complex (RISC) targets a com-
plementary mRNA for site-specific cleavage and sub-
sequent degradation. An 21–22 nucleotide siRNA du-
plex is loaded onto the RISC complex, the siRNA
duplex is unwound, and RISC is activated (RISC*) to
induce RNAi in human cells. Upon recognizing com-
plementary mRNA, RISC* (siRISC*) specifically interacts
with the target mRNA and cleaves the mRNA at a sin-
gle site. To identify new components of the RNAi
pathway, we screened a chemical library of substi-
tuted dihydropteridinones for small molecules that
specifically inhibit RNAi in human cells. From this
screen, a nontoxic, cell-permeable, and reversible in-
hibitor of the RNAi pathway was identified. This com-
pound, called ATPA-18, specifically inhibited an early
step in the RNAi pathway that occurred within 6 hr
of siRNA transfection. These early steps may include
siRNA entry into the RNAi pathways, RISC loading,
and/or siRNA unwinding. ATPA-18 effects were spe-
cific to double-stranded siRNA, and RISC* was not
inhibited when treated with ATPA-18 after unwinding
has occurred. These results demonstrate that the
early steps of RNAi, including siRNA unwinding, are
essential for inducing RNAi, and our findings estab-
lish that siRNA is unwound in cells during a specific
span of time. Taken altogether, ATPA-18 analogs rep-
resent a new class of small molecules that should
prove useful for studying RNAi mechanisms and new
gene functions in vivo in a variety of model or-
ganisms.
Supplemental Data
Supplemental Data include two figures and can be found with this
article online at http://www.chembiol.com/cgi/content/full/12/6/
643/DC1/.
Acknowledgments
We thank members of the Rana Lab for helpful discussions and
Tamara J. Richman for editorial assistance. This work was sup-
ported in part by grants from the National Institutes of Health (AI
41404 and AI 43198) to T.M.R.
Received: December 22, 2004
Revised: April 19, 2005
Accepted: April 19, 2005
Published: June 24, 2005
References
1. Hannon, G.J. (2002). RNA interference. Nature 418, 244–251.
2. Meister, G., and Tuschl, T. (2004). Mechanisms of gene silenc-ing by double-stranded RNA. Nature 431, 343–349.
3. Chiu, Y.L., and Rana, T.M. (2002). RNAi in human cells: basic
Chemistry & Biology
648structural and functional features of small interfering RNA. Mol.
Cell 10, 549–561.
4. Hammond, S.M., Bernstein, E., Beach, D., and Hannon, G.J.
(2000). An RNA-directed nuclease mediates post-transcrip-
tional gene silencing in Drosophila cells. Nature 404, 293–296.
5. Nykanen, A., Haley, B., and Zamore, P.D. (2001). ATP require-
ments and small interfering RNA structure in the RNA interfer-
ence pathway. Cell 107, 309–321.
6. Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R., and
Tuschl, T. (2002). Single-stranded antisense siRNAs guide
target RNA cleavage in RNAi. Cell 110, 563–574.
7. Martinez, J., and Tuschl, T. (2004). RISC is a 5# phosphomonoes-
ter-producing RNA endonuclease. Genes Dev. 18, 975–980.
8. Chiu, Y.L., and Rana, T.M. (2003). siRNA function in RNAi: a
chemical modification analysis. RNA 9, 1034–1048.
9. Elbashir, S.M., Martinez, J., Patkaniowska, A., Lendeckel, W.,
and Tuschl, T. (2001). Functional anatomy of siRNAs for mediat-
ing efficient RNAi in Drosophila melanogaster embryo lysate.
EMBO J. 20, 6877–6888.
10. Hutvagner, G., and Zamore, P.D. (2002). A microRNA in a multi-
ple-turnover RNAi enzyme complex. Science 297, 2056–2060.
11. Song, J.J., Smith, S.K., Hannon, G.J., and Joshua-Tor, L. (2004).
Crystal structure of Argonaute and its implications for RISC
slicer activity. Science 305, 1434–1437.
12. Liu, J., Carmell, M.A., Rivas, F.V., Marsden, C.G., Thomson,
J.M., Song, J.J., Hammond, S.M., Joshua-Tor, L., and Hannon,
G.J. (2004). Argonaute2 is the catalytic engine of mammalian
RNAi. Science 305, 1437–1441.
13. Meister, G., Landthaler, M., Patkaniowska, A., Dorsett, Y., Teng,
G., and Tuschl, T. (2004). Human Argonaute2 mediates RNA
cleavage targeted by miRNAs and siRNAs. Mol. Cell 15, 185–
197.
14. Chiu, Y.L., Cao, H., Jacque, J.M., Stevenson, M., and Rana,
T.M. (2004). Inhibition of human immunodeficiency virus type 1
replication by RNA interference directed against human tran-
scription elongation factor P-TEFb (CDK9/CyclinT1). J. Virol.
78, 2517–2529.
15. Zeng, Y., and Cullen, B.R. (2002). RNA interference in human
cells is restricted to the cytoplasm. RNA 8, 855–860.
16. Kawasaki, H., and Taira, K. (2003). Short hairpin type of dsRNAs
that are controlled by tRNA(Val) promoter significantly induce
RNAi-mediated gene silencing in the cytoplasm of human cells.
Nucleic Acids Res. 31, 700–707.
17. Chiu, Y.L., Ali, A., Chu, C.Y., Cao, H., and Rana, T.M. (2004).
Visualizing a correlation between siRNA localization, cellular
uptake, and RNAi in living cells. Chem. Biol. 11, 1165–1175.
18. Schwarz, D.S., Hutvagner, G., Haley, B., and Zamore, P.D.
(2002). Evidence that siRNAs function as guides, not primers,
in the Drosophila and human RNAi pathways. Mol. Cell 10,
537–548.
19. Clegg, R.M. (2002). FRET tells us about proximities, distances,
orientations and dynamic properties. J. Biotechnol. 82, 177–
179.
20. Bastiaens, P.I., Majoul, I.V., Verveer, P.J., Soling, H.D., and
Jovin, T.M. (1996). Imaging the intracellular trafficking and state
of the AB5 quaternary structure of cholera toxin. EMBO J. 15,
4246–4253.
21. Kenworthy, A.K., and Edidin, M. (1998). Distribution of a glyco-
sylphosphatidylinositol-anchored protein at the apical surface
of MDCK cells examined at a resolution of <100 A using im-
aging fluorescence resonance energy transfer. J. Cell Biol. 142,
69–84.
22. Robb, G.B., Brown, K.M., Khurana, J., and Rana, T.M. (2005).
Specific and potent RNAi in the nucleus of human cells. Nat.
Struct. Mol. Biol. 12, 133–137.
23. Brown, K.M., Chu, C.Y., and Rana, T.M. (2005). Target accessi-
bility dictates the potency of human RISC. Nat. Struct. Mol.
Biol. 12, 469–470.
